Sara Nochur
Direttore/Membro del Consiglio presso MARINUS PHARMACEUTICALS, INC.
Patrimonio netto: 9 017 $ in data 30/04/2024
Posizioni attive di Sara Nochur
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2021 | - |
| Consigliere Generale | 01/01/2006 | 01/01/2021 | |
| MARINUS PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 22/03/2021 | - |
| Independent Dir/Board Member | 22/03/2021 | - | |
| Hospitality Homes | Presidente | 01/01/2021 | - |
| Biomedical Sciences Careers Program, Inc. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Sara Nochur
Precedenti posizioni note di Sara Nochur
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| DECIBEL THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 06/12/2021 | 22/09/2023 |
| Independent Dir/Board Member | 06/12/2021 | 22/09/2023 | |
| THE MEDICINES COMPANY | Consigliere Generale | - | - |
| Biotrack, Inc. | Direttore operativo | - | - |
| Consigliere Generale | - | - | |
| DynaGen, Inc. | Corporate Officer/Principal | - | - |
Ischemix, Inc.
 Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Consigliere Generale | - | - |
Formazione di Sara Nochur
| University of Mumbai | Graduate Degree |
| Massachusetts Institute of Technology | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 11 |
| India | 2 |
Posizioni
| General Counsel | 4 |
| Director/Board Member | 3 |
| Corporate Officer/Principal | 2 |
Settori
| Health Technology | 7 |
| Consumer Services | 2 |
| Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| ALNYLAM PHARMACEUTICALS, INC. | Health Technology |
| MARINUS PHARMACEUTICALS, INC. | Health Technology |
| DECIBEL THERAPEUTICS, INC. | Health Technology |
| Aziende private | 6 |
|---|---|
Ischemix, Inc.
Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Health Technology |
| Biotrack, Inc. | |
| DynaGen, Inc. | Health Technology |
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology The Medicines Co. is a biopharmaceutical company, which focuses on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on acute and intensive care hospitals worldwide. The firm markets its brands Angiomax, Cleviprex, injectable emulsion, Ionsys, Kengreal, Minocin for injection, and Orbactiv. The company was founded by Clive A. Meanwell, Helmut Giersiefen, John W. Villiger and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, NJ. | Health Technology |
| Hospitality Homes | |
| Biomedical Sciences Careers Program, Inc. |
- Borsa valori
- Insiders
- Sara Nochur
- Esperienza
